GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Surge and Magnify Technologies
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Oncology
    • Recombinant Polyclonals
  • Careers
  • Contact
  • Menu Menu

News Archive

Drug Target Review: Intravenous immunoglobulins, hyperimmunes and pandemic viruses

05/04/2020

David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19. Read the full story.

Read more

Nature Biotechnology: Convalescent serum lines up as first-choice treatment for coronavirus

05/01/2020

Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves […]

Read more

TIME: Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About

04/14/2020

It’s not just people and animals that can produce antibodies. Scientists now have the technology to build what are essentially molecular copying machines that can theoretically churn out large volumes of the antibodies found in recovered patients. At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying […]

Read more

WGNO-TV (ABC): Coronavirus Survivors Needed: New Orleans Doctor is collecting blood samples from survivors to make treatment

04/13/2020

Watch the tv news report.

Read more

GEN: Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

04/13/2020

Scientists worldwide are racing to develop more than 160 new drug and vaccine candidates to combat the pandemic, GEN reports in a comprehensive new A-List Read the full story.

Read more

The Lens: Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment

04/08/2020

Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment The race to find a treatment for COVID-19 is in full swing as researchers in labs across the world attempt to unravel the unique properties of this disease, and find ways to neutralize it. To aid in the effort, […]

Read more

Chemical & Engineering News: Searching for a coronavirus cure in the blood: Scientists look to convalescent plasma, hyperimmune therapy, and monoclonal antibodies to treat COVID-19

04/07/2020

Companies say it is too soon to know how many patients can be treated from one plasma donation, but it is likely no more than a few, at best. Emergent is hoping to avoid potential delays in plasma collection by also producing hyperimmune globulins in horses vaccinated with whole or partial bits of SARS-CoV-2. SAB […]

Read more

Pharmaceutical Technology: GigaGen works on recombinant polyclonal antibody against Covid-19

03/31/2020

Biotechnology company GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment. The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus. Read the full story.

Read more

San Francisco Business Times: Peninsula biotech readies attack on COVID-19 — all it needs now is more cash and recovered patients’ blood

03/30/2020

The company thinks it can scale up production of its recombinant polyclonal antibodies in early July, but an actual COVID-19 treatment may be several more months away. Read the full story.

Read more

BioSpace: GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy

03/30/2020

GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19. First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals. Read the full story.

Read more

Big4Bio: GigaGen Focuses Its Technology to Address COVID-19 Pandemic

03/30/2020

GigaGen announced that it is developing a recombinant polyclonal antibody therapy for the treatment of COVID-19, the pandemic coronavirus that has been sweeping the world and for which humans have no innate immunity. Based in South San Francisco, GigaGen spent the first seven years of its existence developing its single cell technology drug discovery and […]

Read more

FierceBiotech: GigaGen jumps into COVID-19 arena with polyclonal antibodies

03/30/2020

Mining the blood of recovered patients for treatments during a pandemic isn’t a new idea. Takeda and Grifols are already doing it, working on antibody-rich drugs made from the plasma of patients who have fought off COVID-19 infection. But a small South San Francisco startup thinks its approach could be even better. Read the full […]

Read more

GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19

03/30/2020

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. Read the full press release.

Read more

Pharma’s Almanac: CEO Dave Johnson shares his thoughts in Roundtable: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?

03/19/2020

The development and rapid advancement of massively parallel sequencing technologies and analytical tools was a major breakthrough for the industry over the 2000s. This technology provided vast volumes of genotypic and phenotypic data, leading to a better understanding of human diseases. A more recent breakthrough is the development of single-cell “omics” technologies, which allow for […]

Read more

GEN: CEO Dave Johnson discusses GigaGen technology in Antibody Screening is Never Out of Sorts

02/03/2020

“The idea behind our approach is that we can run a sample of cells through a microfluidic device that we designed and go very deep into the antibody repertoires,” says David S. Johnson, PhD, CEO and co-founder of GigaGen. The approach developed by GigaGen combines the use of emulsion droplet microfluidics with yeast single-chain variable […]

Read more

Scrip: CEO Dave Johnson Discusses Commercializing Advanced Therapies in Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business and Investment

01/07/2020

With drug price sensitivity persisting, David Johnson, CEO of GigaGen, believes “an important focus for early-stage drug developers will be to innovate in approaches that simultaneously improve patient care and reduce costs to the health system. Drugs that are safer than existing drugs could be priced competitively with incumbents but reduce costs to the health […]

Read more

BioSpace: GigaGen’s Recombinant IVIG Technology Could Be Potential Solution to Global Shortage

12/10/2019

A critical supply shortage of intravenous immunoglobulin (IVIG) in the United States has left some room for doubt about whether or not that critical care will make it to some patients. IVIG contains antibodies that are harvested from plasma provided by thousands of donors across the country. IVIG, which is injected into patients, helps them […]

Read more

Biocom: CSO Adam Adler named a Biocom Catalyst Award Winner

09/23/2019

Biocom, the association representing the California life science industry, today announced the winners of its Fourth Annual Catalyst Awards. The awards identify accomplished and up-and-coming academics, entrepreneurs, investors, corporate leaders and business advisers who are making their mark on the San Diego, Los Angeles and Bay Area life science industries before reaching their 40th birthday. […]

Read more

PharmaVOICE: CEO Dave Johnson named one of the 100 Most Inspiring People

08/02/2019

Big Picture, Big Rewards – David Johnson, Ph.D., locks up his bicycle after a harrowing ride navigating hills and traffic to make his way to South San Francisco, Calif., the birthplace of biotechnology. It’s how he gets to and from work at GigaGen, a company he founded in 2010 to translate his research in single cell […]

Read more

GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies

07/19/2019

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of […]

Read more
Page 2 of 512345

Latest Tweets

GigaGen Follow

Billions of immune cells in your bloodstream fight disease on a daily basis. GigaGen turns these cells into life-saving medical therapies.

gigageninc
GigaGen @gigageninc ·
21 Jun

Polyclonal #AntibodyTherapies contain a variety of antibody types and are ideal for diseases that comprise many targets. We’re developing the first #RecombinantPolyclonal antibody therapies for the treatment of infectious diseases. Learn more: https://bit.ly/38xUi5Z

Reply on Twitter 1539231952494116864 Retweet on Twitter 1539231952494116864 Like on Twitter 1539231952494116864 1 Twitter 1539231952494116864
GigaGen @gigageninc ·
14 Jun

On #WorldBloodDonorDay today, we thank all the blood and #plasma donors worldwide who help to provide a source of lifesaving therapies, including #antibody therapies for patients with #InfectiousDiseases.

Reply on Twitter 1536695417592758273 Retweet on Twitter 1536695417592758273 2 Like on Twitter 1536695417592758273 2 Twitter 1536695417592758273
GigaGen @gigageninc ·
7 Jun

This month, we’re proud to support @CancerResearch’s #CancerImmunotherapyMonth and contribute to developing safer and more effective #immunotherapies for patients in need. Learn about how you can support cancer immunotherapy research this month: https://bit.ly/3MHetgg

Reply on Twitter 1534218665415122944 Retweet on Twitter 1534218665415122944 Like on Twitter 1534218665415122944 Twitter 1534218665415122944
GigaGen @gigageninc ·
27 May

We’re advancing the first recombinant #polyclonal #antibody products to treat patients with #InfectiousDiseases and #immunodeficiencies. Learn more about our work and approach: https://bit.ly/3fTeXj1

Reply on Twitter 1530172179752570880 Retweet on Twitter 1530172179752570880 2 Like on Twitter 1530172179752570880 1 Twitter 1530172179752570880
GigaGen @gigageninc ·
19 May

We are happy to announce the publication of our latest peer-reviewed research article demonstrating the potential of our machine learning platform to improve antibody drug discovery and development. Learn more in our press release here: https://bit.ly/3MpERvb

Reply on Twitter 1527341245416165393 Retweet on Twitter 1527341245416165393 1 Like on Twitter 1527341245416165393 2 Twitter 1527341245416165393
©Copyright 2022 GigaGen. All Rights Reserved. | Privacy Policy | Terms | Disclaimer
  • Twitter
  • LinkedIn
Scroll to top